70 years, 23,000 brains a year, 0.2% mortality
To stand in the lobby of Beijing Tiantan Hospital is to understand, very quickly, that this is a hospital with a single-minded job. The hospital was founded in 1956, but the neurosurgery centre that defines it dates from 1982, when a quiet, meticulous surgeon named Wang Zhongcheng pulled together the country's first proper neurosurgery department. Wang would go on to become the only surgeon in the world credited with performing more than ten thousand open-brain operations — a figure so unusual that colleagues outside China initially assumed it was a typographical error. He won the State Supreme Science and Technology Award in 2008, China's highest scientific honour, and died in 2012.
Today, the Tiantan neurosurgery centre performs more than 23,000 brain operations a year, has a mortality rate of 0.2%, runs nineteen separate sub-specialty units, and has held the No.1 spot in the Fudan Hospital Specialty Reputation Rankings for ten consecutive years. In the 2025 Fudan rankings, it was again named China's leading neurosurgery department, ahead of Huashan Hospital, West China Hospital, and the rest of the field.
What "the place Asia flies to" actually looks like
The 19 sub-specialty units cover almost every major branch of the field. The cerebrovascular unit runs hybrid operating rooms where interventional coiling and open surgical clipping can be performed in the same session, with an aneurysm surgery mortality rate of under 1%. The functional neurosurgery unit, led by Professor Zhang Jianguo, has performed more than 4,000 deep brain stimulation (DBS) procedures — the largest such caseload anywhere in the world — and pioneered a form of subthalamic nucleus stimulation for dystonia. The paediatric unit treats conditions such as medulloblastoma at five-year survival rates that match international benchmarks.
The current director, Professor Jiang Tao, is a member of the Chinese Academy of Engineering and the author of the national guidelines for molecular diagnosis and treatment of glioma, the most common malignant brain tumour. The centre's research on glioma immune therapy reached Nature Medicine in 2024. With 28 national-level research grants and more than 300 million yuan in research funding over the past three years alone, the Tiantan neurosurgery centre operates as a research institution as much as a clinical one.
Why it became No.1
The Tiantan formula rests on three pillars that few of its competitors can match at the same time. First, a half-century of accumulated surgical experience: the brain-stem tumours that are inoperable elsewhere are routinely removed here, with a brain-stem surgery mortality of 1.2%, the figure Wang Zhongcheng drove down from an essentially unmeasured baseline in the 1980s. Second, a depth of sub-specialisation rare outside a handful of Western centres: rather than running a single general neurosurgery department, the centre runs nineteen focused units, each with its own senior surgeons, its own research programme, and its own outcomes. Third, the weight of the national system: Tiantan is the home of the National Center for Neurological Disorders and the National Clinical Research Center for Neurological Diseases, and it chairs China's national quality-control centre for the field. In addition, the centre has held the No.1 spot in China's STEM (Science and Technology Evaluation Metrics) hospital rankings for neurosurgery for seven consecutive years.
The centre's industrial side is just as striking. Together with Tsinghua University, Tiantan's team developed China's own deep brain stimulator — making China only the second country in the world to master the technology, and reducing the cost of the device by 60%. The cheaper device has since been implanted in more than 100,000 Parkinson's disease patients in China.
What this means for international patients
For a foreign patient considering treatment in China, the practical question is usually: can I get in, who will look after me, and how do I trust what I am being told. On the first count, Tiantan runs an international patient office, an English-language website, and a remote consultation service that handled more than 12,000 cases in 2024 alone. On the second, the centre trains more than 200 foreign visiting doctors every year, in collaboration with Harvard Medical School and the International Neuroscience Institute in Hanover. On the third, the specific numbers above — 23,000 operations a year, 0.2% mortality, 4,000 DBS procedures, a national centre designation that no other Chinese hospital holds — are independently verifiable through the Fudan rankings, through the Chinese Academy of Engineering membership rolls, and through the centre's own peer-reviewed publications.
The address is 119 South Fourth Ring Road West, Fengtai District, Beijing. The hospital's English-language site is at bjtth.org. This profile is editorial information based on the sources linked below, not treatment advice; individual outcomes depend on the condition, the team, and the patient.